Crossmark

<scp>O</scp> rkambi® and amplifier co‐therapy improves function from a rare <i> <scp>CFTR</scp> </i> mutation in gene‐edited cells and patient tissue

Crossref DOI link: https://doi.org/10.15252/emmm.201607137

Published Online: 2017-06-30

Published Print: 2017-09

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Molinski, Steven V https://orcid.org/0000-0001-9215-8232
Ahmadi, Saumel https://orcid.org/0000-0002-5800-6945
Ip, Wan

Ouyang, Hong

Villella, Adriana

Miller, John P https://orcid.org/0000-0003-1493-1394
Lee, Po‐Shun

Kulleperuma, Kethika

Du, Kai

Di Paola, Michelle

Eckford, Paul DW

Laselva, Onofrio https://orcid.org/0000-0002-0237-4079
Huan, Ling Jun

Wellhauser, Leigh https://orcid.org/0000-0003-0883-1768
Li, Ellen

Ray, Peter N

Pomès, Régis

Moraes, Theo J https://orcid.org/0000-0001-9968-6601
Gonska, Tanja https://orcid.org/0000-0001-6786-4354
Ratjen, Felix https://orcid.org/0000-0003-4057-6592
Bear, Christine E https://orcid.org/0000-0001-7063-3418
Funding

Funding for this research was provided by:

Cystic Fibrosis Canada

Hospital for Sick Children

Canadian Institutes of Health Research (CIHR MOP‐97954)

Canadian Institutes of Health Research (CIHR GPG‐102171)

Canadian Institutes of Health Research (CIHR MOP‐130461)
License Information

Version of Record valid from 2017-06-30
More Information

Publication History

Received: 2016-10-03

Accepted: 2017-06-06

Published: 2017-06-30